Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Bradyrhizobium japonicum Tetraacyldisaccharide 4'-kinase (lpxK) CSB-YP806676BVW
CSB-EP806676BVW
CSB-BP806676BVW
CSB-MP806676BVW
CSB-EP806676BVW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium japonicum Probable tautomerase bsl7456 (bsl7456) CSB-YP806677BVW
CSB-EP806677BVW
CSB-BP806677BVW
CSB-MP806677BVW
CSB-EP806677BVW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium japonicum Phosphoglucosamine mutase (glmM) CSB-YP806678BVW
CSB-EP806678BVW
CSB-BP806678BVW
CSB-MP806678BVW
CSB-EP806678BVW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium japonicum NAD-dependent protein deacetylase 2 (cobB2) CSB-YP806679BVW
CSB-EP806679BVW
CSB-BP806679BVW
CSB-MP806679BVW
CSB-EP806679BVW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium japonicum Probable acetoacetate decarboxylase 2 (adc2) CSB-YP806680BVW
CSB-EP806680BVW
CSB-BP806680BVW
CSB-MP806680BVW
CSB-EP806680BVW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium japonicum Molybdenum import ATP-binding protein ModC 2 (modC2), partial CSB-YP806681BVW
CSB-EP806681BVW
CSB-BP806681BVW
CSB-MP806681BVW
CSB-EP806681BVW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium japonicum Coenzyme PQQ synthesis protein E (pqqE) CSB-YP806682BVW
CSB-EP806682BVW
CSB-BP806682BVW
CSB-MP806682BVW
CSB-EP806682BVW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium japonicum UDP-N-acetylglucosamine--N-acetylmuramyl- (pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase (murG) CSB-YP806683BVW
CSB-EP806683BVW
CSB-BP806683BVW
CSB-MP806683BVW
CSB-EP806683BVW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium japonicum Probable L-aspartate dehydrogenase (nadX) CSB-YP806684BVW
CSB-EP806684BVW
CSB-BP806684BVW
CSB-MP806684BVW
CSB-EP806684BVW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium japonicum 3-dehydroquinate dehydratase 2 (aroQ2) CSB-YP806685BVW
CSB-EP806685BVW
CSB-BP806685BVW
CSB-MP806685BVW
CSB-EP806685BVW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium japonicum Formamidase (amiF) CSB-YP806686BVW
CSB-EP806686BVW
CSB-BP806686BVW
CSB-MP806686BVW
CSB-EP806686BVW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium japonicum Flagellar L-ring protein 1 (flgH1) CSB-YP806687BVW
CSB-EP806687BVW
CSB-BP806687BVW
CSB-MP806687BVW
CSB-EP806687BVW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium japonicum Alanine--tRNA ligase (alaS), partial CSB-YP806688BVW
CSB-EP806688BVW
CSB-BP806688BVW
CSB-MP806688BVW
CSB-EP806688BVW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium japonicum Xanthine phosphoribosyltransferase (gpt) CSB-YP806689BVW
CSB-EP806689BVW
CSB-BP806689BVW
CSB-MP806689BVW
CSB-EP806689BVW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium japonicum 50S ribosomal protein L7/L12 (rplL) CSB-YP806690BVW
CSB-EP806690BVW
CSB-BP806690BVW
CSB-MP806690BVW
CSB-EP806690BVW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium japonicum 30S ribosomal protein S10 (rpsJ) CSB-YP806691BVW
CSB-EP806691BVW
CSB-BP806691BVW
CSB-MP806691BVW
CSB-EP806691BVW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium japonicum 30S ribosomal protein S17 (rpsQ) CSB-YP806692BVW
CSB-EP806692BVW
CSB-BP806692BVW
CSB-MP806692BVW
CSB-EP806692BVW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium japonicum 50S ribosomal protein L18 (rplR) CSB-YP806693BVW
CSB-EP806693BVW
CSB-BP806693BVW
CSB-MP806693BVW
CSB-EP806693BVW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium japonicum Oxaloacetate decarboxylase (bll5266) CSB-YP806694BVW
CSB-EP806694BVW
CSB-BP806694BVW
CSB-MP806694BVW
CSB-EP806694BVW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium japonicum Putative Holliday junction resolvase (blr5094) CSB-YP806695BVW
CSB-EP806695BVW
CSB-BP806695BVW
CSB-MP806695BVW
CSB-EP806695BVW-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>